New drug combo for advanced stomach cancer with CLDN18.2
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach cancer, gastroesophageal junction cancer, or esophageal cancer that has not been treated before.
- Your tumor must test positive for a protein called Claudin18.2 (CLDN18.2).
- Your tumor must also be tested for PD-L1 (a protein that tells if you might benefit from immunotherapy).
- You must be in good physical condition (ECOG 0 or 1), meaning you can carry out daily activities with little or no help.
- Your cancer must not be HER2-positive (a different type of protein).
- You must be at least 18 years old and weigh at least 35 kg (about 77 lbs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This trial tests a new combination of two drugs—one targets EGFR on cancer cells, and the other boosts your immune system—for people with advanced stomach or GEJ cancer whose tumors are EGFR-positive and have already tried one prior chemotherapy.
This trial tests a combination of experimental drugs (IBI343, Sintilimab, and chemotherapy) before and after surgery for a specific type of stomach cancer that is CLDN18.2 positive. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.